The 9.1% weight loss at Day 54 without plateau is a strong early signal for DA-1726, positioning it as a potentially competitive GLP1R/GCGR dual agonist. Monitor Q4 2026 higher-dose Part 3 results for durability and safety at higher exposures. Vanoglipel combination data adds optionality but remains preclinical. The stock may see near-term momentum from the ADA presentation, but clinical-stage biotech risk remains high.
Price Chart
Executive Summary
MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg cohort) at ADA 2026, showing 9.1% mean body weight reduction at Day 54 with no plateau, and preclinical vanoglipel combination data demonstrating synergistic weight loss and hepatoprotective effects in MASH/T2D models. The data is clinically meaningful for a Phase 1 obesity asset but remains early-stage, with higher-dose Part 3 results expected in Q4 2026.
Key Facts
- DA-1726 48 mg cohort achieved 9.1% mean body weight reduction at Day 54 (p<0.05 vs placebo at Day 26) with no evidence of plateau
- Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo)
- No treatment-related discontinuations or serious adverse events in the 48 mg cohort
- Vanoglipel + resmetirom combination achieved 23.6% body weight reduction vs control in preclinical MASH model (p<0.05)
- Vanoglipel + metformin reduced non-fasting glucose by 28.7% and body weight by 16.3% vs control (p<0.05)
- Higher-dose Part 3 titration study results expected in Q4 2026
Financial Impact
No financial data reported; market cap is $13M. Positive clinical data may drive valuation re-rating if DA-1726 continues to show competitive weight loss profile.
Risk Factors
- Data is from a small Phase 1 cohort (48 mg); larger and longer-term studies needed to confirm durability and safety
- No plateau observed yet, but follow-up is only through Week 8 — longer-term weight loss trajectory is unknown
- Vanoglipel data is preclinical; clinical validation in MASH/T2D is years away
- Company has a $13M market cap and likely needs to raise capital to fund ongoing trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-071211 |
| Document: mtva-20260608xex99d1.htm | 0001104659-26-071211 |
| Document: 0001104659-26-071211-index-headers.html | 0001104659-26-071211 |
| Document: 0001104659-26-071211-index.html | 0001104659-26-071211 |
| Document: 0001104659-26-071211.txt | 0001104659-26-071211 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.22 (−10.66%) |
Oct 13, 2026 13d ago | 8-K | $1.43 | awaiting T+20 | — | $1.22 (−15.03%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.22 (−30.17%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.22 (−29.77%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.22 (+17.91%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.22 (−35.71%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.22 (−45.27%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.22 (−63.62%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.22 (+9.46%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.22 (+9.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers